Bayer: 5 key drugs to have combined peak sales of 5.5 billion euro

LEVERKUSEN, Germany Wed Nov 14, 2012 3:17pm IST

A man rides a bicycle in front of the building of Germany's largest drugmaker Bayer HealthCare Pharmaceuticals in Berlin April 28, 2011. REUTERS/Fabrizio Bensch

A man rides a bicycle in front of the building of Germany's largest drugmaker Bayer HealthCare Pharmaceuticals in Berlin April 28, 2011.

Credit: Reuters/Fabrizio Bensch

Related Topics

Stocks

   

LEVERKUSEN, Germany (Reuters) - Bayer said its five most promising new drugs have an annual peak sales potential of more than 5.5 billion euros ($7 billion).

The sales forecast comprises anti-clotting pill Xarelto, ophthalmic drug Eylea, also calle VEGF Trap-Eye, anti-cancer products Alpharadin and Stivarga, as well as lung treatment riociguat.

Last year, Bayer said four of the drugs, excluding riociguat, would have a peak sales potential of more than 5 billion euros.

(Reporting by Frank Siebelt; Writing by Ludwig Burger)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Ebola Outbreak

HEALTH SHOWCASE

E-cigarettes

E-cigarettes

WHO urges stiff regulatory curbs on e-cigarettes.  Full Article 

Weighty Issues

Weighty Issues

More parents think their overweight child is 'about right'.  Full Article 

Cancer Drug

Cancer Drug

Pfizer to test Xalkori lung cancer drug with Merck immunotherapy.  Full Article 

Mental Health

Mental Health

Obama tells veterans better mental health care on the way.  Full Article 

Food Regulation

Food Regulation

Russian food safety regulator shuts fifth McDonald's restaurant.  Full Article 

Heinz Recall

Heinz Recall

Heinz recall brings food tracking issue to the fore in China.  Full Article 

Delaying Start

Delaying Start

Delay morning school start for teens: pediatricians.  Full Article 

Birth Control

Birth Control

U.S. moves to ensure birth control access at religious companies.  Full Article